Durable 52-Week Visual and Functional Gains Following First-in-human ZM-02 Optogenetic Therapy for Advanced Retinitis Pigmentosa (ASGCT 2026) - Mar 22, 2026 - Abstract #446; 287; Pres time: May 15, 2026; 08:45 AM - 09:00 AM; Location: MCEC Room 257AB (Level 2); P1 | "MLSDT, Multi-luminance Shape Discrimination Test. MLTs, Multi-luminance Tests, including MLMT, MLCBT, and MLSDT."
First-in-human • Metastases • P1 data • Gene Therapies • Genetic Disorders • Inflammation • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa • Uveitis
|
|
Wenhui Zhou1; Menghan Zhou1; Mojtaba Shirinzadeh1; Haihan Zhang2; Shiyi Yin2; Jingyun Liu3; Shiqiang Zhao2; Fengchao Zhou2; Shiqiang Gao4; Yang Wu3; Sen Jin3; Jingjing Cao3; Laichun Lu2; Alvin Luk3; David Gao3; Wenbin Wei2; Yin Shen1,3
|